Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 51,115 Shares

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 51,115 shares of the firm’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $0.94, for a total transaction of $48,048.10. Following the sale, the insider now owns 326,904 shares in the company, valued at approximately $307,289.76. This trade represents a 13.52 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Jonathan Zalevsky also recently made the following trade(s):

• On Tuesday, November 19th, Jonathan Zalevsky sold 7,785 shares of Nektar Therapeutics stock. The shares were sold at an average price of $1.01, for a total value of $7,862.85.

Nektar Therapeutics Stock Performance

Shares of NKTR stock opened at $0.93 on Friday. Nektar Therapeutics has a fifty-two week low of $0.46 and a fifty-two week high of $1.93. The company has a market capitalization of $171.23 million, a P/E ratio of -1.11 and a beta of 0.57. The stock has a 50 day moving average price of $1.19 and a two-hundred day moving average price of $1.24.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on NKTR shares. BTIG Research reiterated a “buy” rating and issued a $4.00 price objective on shares of Nektar Therapeutics in a report on Monday, September 30th. Piper Sandler initiated coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They set an “overweight” rating and a $7.00 price target on the stock. Finally, HC Wainwright started coverage on shares of Nektar Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $6.50 price objective for the company. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $4.10.

Institutional Investors Weigh In On Nektar Therapeutics

Several institutional investors have recently added to or reduced their stakes in NKTR. SG Americas Securities LLC grew its position in shares of Nektar Therapeutics by 30.4% in the 3rd quarter. SG Americas Securities LLC now owns 95,637 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 22,285 shares during the last quarter. Victory Capital Management Inc. bought a new stake in Nektar Therapeutics in the second quarter valued at $29,000. Valence8 US LP purchased a new position in Nektar Therapeutics during the 3rd quarter valued at $34,000. Jane Street Group LLC raised its holdings in Nektar Therapeutics by 50.0% in the 3rd quarter. Jane Street Group LLC now owns 91,470 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 30,481 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Nektar Therapeutics in the 3rd quarter worth about $41,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.